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Abstract 
 
Objectives  
 
To investigate the effects, costs and feasibility of providing on-site compared with remote 
meetings to set-up hospital sites in a multi-centre, surgical randomised controlled trial. 
 
Study Design and Setting  
 
Hospitals were randomised to receive the initial trial set-up meetings on-site (i.e. face-to-
face) or remotely (i.e. via teleconference). Data were collected on site set-up, recruitment, 
follow-up and costs for the two methods. The hospital staff experience of trial set-up was 
also surveyed. 
 
Results 
 
Thirty-nine sites were randomised and 33 sites set-up to recruit (19 on-site and 14 remote). 
For sites randomised to an on-site meeting compared with remote meeting respectively, the 
time from first contact to first recruit was a median of 246 days [interquartile range (IQR) 196 
to 346] vs 212 days [IQR 154 to 266], mean recruitment was 10 participants [median 10, IQR 
2 to 17] vs 11 participants [median 6, IQR 5 to 23] and participant follow-up at 12 months 
was 81% vs 82%. Sites allocated to an initial on-site visit cost on average £289.83 more to 
set-up.  
 
Conclusion 
 
Remote or on-site visits are feasible for the initial set-up meetings with hospitals in a multi-
centre surgical trial. This embedded trial should be replicated to improve generalisability and 
increase statistical power using meta-analysis. ISRCTN78899574. 
 
Keywords: Study Within a Trial; Randomised Controlled Trial; Recruitment; Response rate; 
Costs; Feasibility 
 
A running title: Remote and on-site visits were feasible for the initial set-up meetings with 
hospitals in a multi-centre surgical trial 
 
Word count: 3886 
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“What is new?” 
 
Key findings: 
 
• It was feasible to use remote or on-site visits for the initial contact with sites when 
setting up hospitals in a multi-centre surgical trial. 
 
What this adds to what was known? 
 
• The evidence from this study and the wider literature questions the need for on-site 
visits and the effectiveness of additional contact by Trial Co-ordinators on trial 
conduct. 
 
What is the implication, what should change now? 
 
• Trial Co-ordinators should consider being more selective as to when on-site visits are 
necessary and what type of additional contact with a site is required depending on 
the challenges that are specific to that site and the study.  
• Further research is necessary to improve our understanding of what constitutes 
optimal Trial Co-ordinator contact with sites and to evaluate strategies across a 
range of participant groups and settings. 
 
1. Introduction 
 
Randomised controlled trials (RCTs) are the gold standard for evaluating the effectiveness 
and safety of healthcare interventions (Kunz et al, 2007). They often require substantial 
amounts of public funds, but around half fail to reach their recruitment target within their 
original timescale and budget (Walters et al. 2017). Poor recruitment can lead to 
underpowered studies that can increase the risk of not implementing an effective 
intervention. This raises ethical concerns about the involvement of participants in RCTs and 
can lead to a trial being extended which increases costs (Treweek et al. 2013).  
 
In our experience, setting up hospital sites to recruit into multi-centre RCTs usually requires 
an initial contact meeting between the Trial Co-ordinator (TC) and hospital staff to discuss: i) 
the trial rationale and design; ii) assessment of feasibility and capacity of the site to deliver 
the trial; and iii) the submission for local governance approval to undertake the trial. This is 
followed by a site initiation visit (SIV), which is often conducted on-site (face-to-face), during 
which hospital staff are trained in trial procedures and checks are made to ensure that the 
necessary practical and governance arrangements are in place to start the trial.  
 
We have often conducted the initial contact meeting on-site; although it could be undertaken 
remotely (via telephone/videoconference). The potential benefit of both the initial contact and 
SIV being on-site is to help foster a positive relationship between the trial team and site staff, 
expedite the timeliness with which sites are set-up and improve recruitment and data 
collection. However, in multi-centre RCTs it can be very time-consuming and costly for TCs 
to conduct both visits face-to-face for each site. Evidence from a single embedded RCT 
suggested that conducting on-site monitoring visits compared with no visit did not statistically 
significantly improve participant recruitment or data collection (Lienard et al. 2006).  
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Given the limited evidence available and the increasing demand from commissioners of 
research for more efficient RCTs, we decided to explore the feasibility of undertaking 
remote, rather than on-site, initial contact meetings when setting up hospitals. This study 
within a trial (SWAT) was embedded in the SWIFFT multi-centre, orthopaedic surgical trial 
(Dias et al. 2016) and was registered as number 27 (ISRCTN 78899574) with the Northern 
Ireland Hub for Trials Methodology Research programme.  The protocol is publically 
available on-line at their SWAT Repository Store. The objectives were to investigate whether 
a remote meeting compared with an on-site visit was feasible for the initial contact with 
hospitals and to describe the effect on set-up times, recruitment, data collection and the 
costs of these two approaches.  
 
2. Methods  
 
2.1 Population, design and interventions 
 
A feasibility RCT of on-site (face-to-face) versus remote (teleconference) initial contact 
meetings with hospital sites was embedded within the SWIFFT trial.  SWIFFT is evaluating 
the clinical and cost-effectiveness of cast treatment versus surgical fixation in patients aged 
16 or above with a clear bicortical fracture of the scaphoid waist on plain radiographs from 
hospital sites predominantly across England. Patients were recruited at fracture clinics and 
were asked to complete a questionnaire by post or in clinic at 6, 12, 26 (post only) and 52 
weeks (primary end-point). Patients attended hospital out-patient clinics at 6, 12 and 52 
weeks when data on treatment, grip strength, range of movement, complications and 
imaging were collected.  
 
The initial contact meeting between the TC and hospital site was standardised across the 
two groups by: i) inviting the same staff at each site (the site-specific Principal Investigator 
(PI), Research Nurse (RN) and, where possible, Radiology contact) to discuss preparing the 
site for submission to local Research and Development (R&D) departments for study 
approval, using a pre-defined email depending on site allocation; ii) using the same 
presentation for each mode of meeting; and iii) devising a checklist to ensure all the same 
topics were discussed. All subsequent SIVs were held on-site for both groups. 
 
The study complies with guidelines for reporting embedded recruitment trials (Madurasinghe 
et al. 2016).  
 
2.2 Randomisation and Sample Size 
 
Sites were randomised 1:1 to receive either an on-site or remote initial contact meeting using 
minimisation (via MinimPy software, Saghaei and Saghaei, 2011) based on: i) the size of the 
hospital catchment area (small [population <500,000]/large [population ≥500,000]); ii) 
whether the PI had previous experience of working on a RCT; and iii) whether the site had a 
RN in place. The randomisation was conducted by a statistician at York Trials Unit, 
University of York (the trial co-ordinating centre) at the point when new sites were identified 
to be approached.  
 
While group allocation could not be blinded, participating sites were not aware of their 
involvement in this embedded trial. The hospital site of the Chief Investigator and Sponsor 
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was excluded because of their substantial involvement in setting up the embedded and host 
trials. Two sites in the same geographical area shared the same PI; therefore, to maintain 
blinding, both sites were allocated to the same group. In order not to jeopardise the setting 
up of trial sites for SWIFFT, the trial team did not insist that the initial contact meeting should 
be on-site or held remotely if the PI had a preference for how to meet.  
 
As is common in embedded trials, no formal power calculation was conducted as the sample 
size was restricted by the number of hospitals taking part in SWIFFT.  
 
2.3 Outcomes  
 
There was no single primary outcome. A range of outcomes were explored relating to set-up, 
recruitment, and follow-up. 
 
Site-level outcomes comprised: time from first contact with a site to (i) submission of local 
R&D application, (ii) receipt of R&D approval, (iii) final on-site SIV and (iv) first randomised 
participant, as well as the number of patients screened and the proportion of eligible patients 
who were randomised. Patient-level outcomes were the return, and time to return, of the grip 
and range hospital form (as completion of this form required the patient to attend hospital) 
and participant questionnaires by follow-up time point (for the latter either collected at the 
hospital or via post which could include a 2 and 4 week reminder letter and 6 week 
telephone call). 
 
2.4 Time and costs 
 
The time that TCs spent communicating with each site (via email, telephone, attending an 
on-site visit [door-to-door]) was entered into a spreadsheet. This started from when the site 
was formally invited to begin the process of being set-up until the ‘greenlight’ was given to 
recruit i.e. it included both the initial meeting (whether on-site or remote) and the follow-up 
on-site SIV. The cost of each of these methods of communication was calculated by 
multiplying the time in hours spent by a basic hourly rate for a TC at an appropriate pay 
grade that included employer contribution to National Insurance and pension (£27.85/hour). 
The total cost of travel (i.e. transport, hotel, subsistence) was calculated and communication 
and travel costs were summed to produce a total cost of setting up each site.  2.5 Site 
preferences 
 
When recruitment of trial participants into SWIFFT was completed in July 2016 we emailed a 
survey to collaborators (PIs, RNs, Research Physiotherapists (RPs), Surgeons, etc) at the 
participating sites to explore their experience of setting up the SWIFFT trial. This brief 10 
item questionnaire was created on-line using Qualtrics software (Utah, USA, 2017) and 
focussed on understanding preferences towards the need for a remote or on-site visit both 
for the initial contact meeting and SIVs. Participation was voluntary and responses were 
anonymised. As a small incentive to take part, respondents could enter a free prize draw to 
receive a box of chocolates.   
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2.6 Statistical Analysis 
 
The main analyses were conducted on an intention-to-treat (ITT) basis including all sites in 
the groups they were assigned to at randomisation. Analyses were conducted in Stata 
version 13 (StataCorp, 2013) using two-sided statistical tests at the 5% significance level. 
 
Since this was an embedded, feasibility trial, outcomes were not formally compared and 
were summarised descriptively overall and by trial arm.  
 
To investigate the effect of non-compliance with random group allocation, descriptive 
analyses were repeated on a per-protocol (PP) basis removing sites that crossed over to the 
alternative mode of delivering the meeting.  
 
Communication time and costs for communication and travel were reported descriptively by 
trial arm and in total. Survey responses were summarised for individual items by trial arm 
and relevant free text comments were highlighted. 
 
2.7 Ethical considerations 
 
Sites did not know they were taking part in this embedded trial. All sites received as much 
training in trial procedures and governance issues as required ensuring there were no ethical 
concerns about the recruitment and follow-up of trial participants.  
 
3. Results 
 
Forty sites were approached to take part in SWIFFT between May 2013 and March 2015 
(Figure 1). The CI’s site was not included. Therefore, 39 sites were randomised: 20 to on-
site initial contact meetings (including one site that was manually allocated to the same site 
as its sister site sharing the same PI) and 19 to remote initial contact meetings. Two sites 
(both allocated to remote) were excluded post-randomisation because agreement had not 
been reached to formally take part in SWIFFT. This resulted in 37 eligible, randomised sites 
(20 on-site; 17 remote) that could be included in the main analyses. Half the sites served 
‘large’ populations (n=18, 49%), two-thirds had a PI with previous experience of working on 
a multi-centre trial (n=25, 68%), and two-thirds had RN support (n=25, 68%; Table 1).  
Minimisation ensured that the two groups were well balanced on these characteristics.    
 
3.1 Site set-up 
 
Four (11%) of the 37 sites withdrew their interest in the trial before applying for R&D 
approval (3 remote and 1 on-site). For the remaining 33 sites, it took a median of 119 days 
(interquartile range (IQR) 75 to 189 days) after first contact to submit to R&D (median 113 
days on-site and 134 days remote; Table 2). R&D approval was granted a median of 139 
days and 155 days after first contact with on-site and remote sites, respectively. SIVs took 
place a median of 126 days (IQR 89 to 196 days) after first contact (median 119 days on-site 
and 142 days remote).   
 
In total, 33 of the 37 (89%) sites opened to recruitment (on-site: n=19, 95%; remote: n=14, 
82%); however, three (all allocated to on-site visits) withdrew their interest in recruiting for 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
8 
 
SWIFFT following the SIV (two of whom had commenced screening but had not recruited a 
patient). For the 30 sites who recruited at least one SWIFFT participant, the first recruit 
occurred after a median of 229 days (IQR 188 to 319 days) from first contact with the sites 
(median 246 days on-site and 212 days remote; Table 2). 
 
3.2 Recruitment 
 
A median of 22 eligibility forms per site (IQR 5 to 38) were returned (Table 3) and a total of 
378 patients were recruited. The median consent rate of patients was 0.63 for the on-site 
group and 0.53 for the remote group. The mean number of participants recruited was 10 for 
the on-site group and 11 for the remote group. Figure 2 shows that recruitment data were 
positively skewed with a median of 6 across all sites (range from 0 to 35, median of 10 [IQR 
1.5 to 17] and 6 [IQR 5 to 23] participants for on-site and remote groups, respectively; Table 
3). There were 406 days (13 months) when all sites were open for recruitment. During this 
time, a median of 4 participants were recruited per site in the on-site group (IQR 0 to 5.5; 
Table 3), and 2 per site (range 1 to 5) in the remote group (total 68 in the on-site group and 
79 remote). 
 
3.4 Follow-up 
 
The percentage of participant questionnaires returned at weeks 6 and 52 appear similar 
between the on-site and remote groups; however, there is a slight difference at weeks 12 
(80.2 vs 84.5%) and 26 (68.4 vs 74.6%) favouring the remote group (Table 4).  For the 
hospital grip and range form, the percentage returned is similar between the two groups at 
week 6, but favours the remote group at weeks 12 and 52 (73.6 vs 80.5%, and 65.3 vs 
70.8%, respectively).  For returned forms and questionnaires, the median number of days 
between the due date and the date of return does not differ between the two groups by more 
than 5 days at any time point.  
 
3.5 Per-protocol (PP) results 
 
In total, there were three cross-overs because of site preferences: two on-site to remote; and 
one remote to an on-site visit. Therefore, in the PP analyses, there were 18 sites in the on-
site group and 16 in the remote group. Reasonable balance between the two groups was 
retained for size of the hospital catchment area (large population: on-site 44%; remote 50%); 
previous PI trial experience (Yes: on-site 67%; remote 69%); and presence of RN support 
(Yes: on-site 67%; remote 69%). Results of the PP analyses found that whilst in the ITT 
analysis the median time to R&D approval was less in the on-site group, in the PP analysis it 
was less in the remote group (139 days vs 135). Among sites receiving an on-site or remote 
visit respectively, mean recruitment was 10 participants [median 10, IQR 2 to 17] and 11 
participants [median 5.5, IQR 4.5 to 23.5].        
 
3.6 Time and costs 
 
Trial Co-ordinators spent more time, on average, on the telephone corresponding with sites 
in the remote group (1.6 hours) compared with the on-site group (0.9 hours; Table 5). 
Conversely, more time was spent, on average, attending face-to-face visits in the on-site 
group (20.9 hours) compared with the remote group (12.9 hours). In the on-site group, one 
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site received 0 face-to-face visits, 2 received 1 visit, 16 received 2 visits, and 1 received 3 
visits (37 in total); and in the remote group, two sites received 0 face-to-face visits, 14 
received 1 visit, and 1 received 2 visits (16 in total). The average amount of time spent 
emailing sites was the same for the two groups (5.3 hours). Overall more time, on average, 
was spent setting up sites in the on-site group (27.2 hours) than the remote group (19.9 
hours).  
 
The cost of staff time to communicate with sites in the on-site group was more, on average, 
than the remote group (£757.10 vs £553.90; Table 6). The total cost overall, excluding travel, 
of the initial contact visits was £24,560 (£15,143 on-site and £9,417 remote). The total cost 
overall, including travel, was £32,700 (£20,339 on-site and £12,361 remote).  Including 
additional travel costs, the average cost of setting up a site in the remote group was £727.10 
compared with £1016.93 in the on-site group, a difference of £289.83.  
 
3.7 Site preferences 
 
We invited 96 collaborators to complete the survey. There were 12 respondents (from 9 of 
17 sites) in the remote group and 16 respondents from (12 of the 20 sites) in the on-site 
group i.e. there were respondents from 21 of 37 (57%) sites. For the remote group 
respondents comprised five PIs, three RNs, one RP and two Surgeons with an average of 7 
years (range 1.5 to 18) experience with RCTs. For the on-site group respondents comprised 
seven PIs, five RNs, three RPs and one Surgeon with an average of 5 years (range 1 to 12) 
experience with RCTs. 
    
Only 2 of 12 respondents from the remote group indicated they would have preferred the 
initial contact meeting to be held on-site and half felt a remote meeting was sufficient. Most 
of the respondents in the on-site group (10 of 16) felt the initial contact meeting could have 
been held remotely; only 2 thought it needed to be on-site. Free text comments from both 
groups illustrated that whilst the on-site meetings help with communication (7 respondents) 
information could be adequately exchanged remotely at this stage of site set-up (8 
respondents). For the final SIV meeting, the preference overall was for an on-site visit (17 of 
28 respondents); although this was preferred more in the remote group (9 of 12 
respondents) compared with the on-site group (8 of 16 respondents).  
 
4. Discussion 
 
We undertook a SWAT comparing on-site with remote meetings for the initial contact with a 
potential recruiting hospital in the SWIFFT trial. We considered set-up times, recruitment, 
data collection, the costs of the two approaches and the views of the hospital staff. 
 
Hospitals allocated to receive an on-site visit met key milestones earlier, except for the time 
to first recruit. The on-site group took around a month later to recruit their first participant; 
overall it took around eight months to set-up a hospital site. Measures of recruitment were 
similar between the two groups. The on-site group (20 sites) and remote group (17 sites) 
recruited in total 193 and 185 participants, respectively i.e. a difference of 8 patients in total 
compared with the average of 12 participants recruited a month into the trial. The mean 
number of participants recruited per site was comparable, but the median recruited was 
around twice as high in the on-site group. This is because the number of participants 
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recruited per site was more uniform in the on-site group; whereas for the remote group most 
sites recruited around 0 to 10 participants and a few sites recruited around 20 to 35 
participants. With the small number of hospitals involved it is difficult to conclude whether 
this difference in the distribution of recruitment is caused by the site having a remote 
meeting or by chance. There were no notable differences between the two groups in the 
timeliness of the return of hospital forms or participant questionnaires; some differences 
were observed in the proportion of participant questionnaires returned at weeks 12 and 26, 
and hospital forms at weeks 12 and 52, favouring the remote group. 
 
Nearly twice the amount of time was spent by TCs on the telephone in the remote group, 
and nearly twice the amount of time attending face-to-face visits in the on-site group. In total, 
around one extra working day was spent by a TC setting up a hospital in the on-site group, 
equating to a months’ work over 20 sites. The travel costs were also higher in the on-site 
group. This on average resulted in sites in the on-site group costing £289.83 more to set-up 
than sites allocated to a remote meeting. With the on-site group recruiting on average 1.2 
fewer patients, this was a cost saving of approximately £242 per extra participant recruited 
for the remote group. However, data for number of participants recruited were skewed and 
so using the median, rather than the mean, the on-site group set-up costs an extra £72 per 
extra recruit. The response to the survey of collaborators found that the majority felt the 
initial meeting did not need to be face-to-face as information could be adequately exchanged 
remotely at this stage of site set-up. Not having an initial on-site visit meant the majority in 
the remote group did prefer the SIV to be on-site; the on-site group were split about this 
having already met. Overall, these findings provide evidence that it is feasible to undertake 
an initial contact meeting remotely and to undertake an embedded trial to inform trial 
conduct.  
 
A systematic review of quasi-randomised and RCTs of interventions designed to improve 
recruitment into RCTs in both real and hypothetical settings identified 45 embedded trials 
with around 43,000 participants (Treweek et al, 2013). This compares with over one million 
records of trials on the Cochrane Central Register of Controlled Trials as of August 2017. 
Initiatives like START (Rick et al, 2014) and SWAT (Anonymous, 2012) are important to 
further encourage the conduct of embedded trials. Of the 45 embedded trials, two studies 
(302 trial sites) looked at the effect of greater contact from TCs. Both studies were assessed 
as low risk of bias. One RCT in France about breast cancer found that in 68 of the 135 
participating hospital sites that received on-site visits there was no statistically significant 
difference in the number of trial participants recruited (302 in the Visited group versus 271 in 
the Non-visited group) (Lienard et al. 2006). A second international RCT about patients with 
diabetes and vascular disease with 167 centres found that the median number of recruits at 
sites that had additional communication from the co-ordinating centre compared with usual 
communication was 37.5 vs 37.0, respectively (p=0.68) (Monaghan et al, 2007). A further 
study found that at the site chosen to be visited by the lead researcher recruitment target 
rates increased post-intervention by 17% (p=0.01) and 14% (p=0.002) at 1 and 3 months 
respectively. No statistically significant difference occurred at either of the two other sites 
that had no visit (Smith et al, 2014). The study, however, was limited by a retrospective 
controlled before and after design, only involved three sites with a short follow-up 
assessment and the intervention site was selected because of reduced recruitment in the 
past months and therefore improvement could be attributed to regression to the mean. 
Taken together, the findings from this embedded trial and other studies questions how 
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effective and efficient is it for TCs to continue to invest limited time and resources with on-
site visits and additional contact with a site? It might be that TCs should be more selective 
about when on-site visits are necessary and a different type of additional contact and 
strategy is required depending on the challenges that are specific to that site and study. 
Further research is necessary to improve our understanding of what constitutes optimal TC 
contact with sites and to evaluate strategies across a range of participant groups and 
settings.     
 
Finally, we undertook an embedded trial to attempt as much as was feasible to rigorously 
answer this question and collected data on a variety of important outcomes and costs. The 
study was limited, however, by the number of sites involved and restricted to an orthopaedic, 
surgical trial setting. Furthermore we continued recording all the communication and travel 
with a site only until it was set-up to recruit. The perspective of the cost analyses is that of 
the trials unit without considering how the two different approaches may have affected the 
time and cost of setting up a site to the hospital. It is unlikely that it would change the results 
as the time spent communicating should be similar and the cost of travel was to the trials 
unit. This embedded trial was undertaken around when the Clinical Research Network in 
England introduced metrics about time taken for a study to start at a site and recruit the first 
participant. Hospital sites were also set-up before the new Health Research Authority 
process for undertaking research in England had been implemented.  
 
5. Conclusions 
 
We have demonstrated that it was feasible to conduct an embedded trial to explore efficient 
trial conduct in a host trial. Holding the initial contact meeting remotely did not appear to 
adversely affect set-up times, screening and recruitment, nor data collection. Any extra cost 
or saving of the two approaches was modest, although a remote initial visit may save TCs’ 
time to set up a site. Our collaborators at hospital sites were amenable to the initial contact 
meeting being held remotely. Evidence from the wider literature also questions the 
effectiveness of on-site visits and additional contact by TCs on trial conduct. Further 
embedded trials about the type and extent of TC contact with sites in different patient 
populations and settings would permit a meta-analyses to increase statistical power and to 
extend the generalisability of the evidence.  
 
Acknowledgements 
 
We thank the hospital sites who participated in the SWIFFT trial and the collaborators at 
hospital sites who responded to the survey. We are grateful to Katherine Chatterton who 
created the on-line survey using Qualtrics software. 
 
References 
 
Anonymous. Education section-Studies Within A Trial (SWAT). J Evid Based Med 2012; 
5(1):44-5.  
 
Dias J, Brealey S, Choudhary L, Cook L, Costa M, Fairhurst C, et al. Scaphoid Waist Internal 
Fixation for Fractures Trial (SWIFFT) protocol: a pragmatic multi-centre randomised 
controlled trial of cast treatment versus surgical fixation for the treatment of bi-cortical, 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
12 
 
minimally displaced fractures of the scaphoid waist in adults. BMC Musculoskelet Disord 
2016;17: 248. 
 
Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare 
trials. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 
10.1002/14651858.MR000012.pub2]  
 
Lienard JL, Quinaux E, Fabre-Guillevin E, Piedbois P, Jouhaud A, Decoster G, et al. Impact 
of on-site initiation visits on patient recruitment and data quality in a randomized trial of 
adjuvant chemotherapy for breast cancer.  Clin Trials 2006;3(5):486-492. 
 
Madurasinghe VW and Sandra E (on behalf of MRC START Group), and Gordon Forbes (on 
behalf of the START Expert Consensus Group). Guidelines for reporting embedded 
recruitment trials. Trials 2016; 17:27. 
 
Monaghan H, Richens A, Colman S, Currie R, Girgis S, Jayne K, et al. A randomised trial of 
the effects of an additional communication strategy on recruitment into a large-scale, multi-
centre trial. Contemp Clin Trials 2007;28:1–5. 
 
Qualtrics. Qualtrics Survey Software Version: 7/10/2017. Provo, UT: Qualtrics LLC. 2017. 
 
Rick J, Graffy J, Knapp P, Small N, Collier D, Eldridge S, et al. Systematic techniques for 
assisting recruitment to trials (START): study protocol for embedded, randomized controlled 
trials. Trials 2014;15:407. 
 
Saghaei M, Saghaei S. Implementation of an open-source customizable minimization 
program for allocation of patients to parallel groups in clinical trials. Journal of Biomedical 
Science and Engineering 2011;4:734-739. 
 
Smith V, Clarke M, Begley C, Devane D. SWAT-1: The effectiveness of a ‘site visit’ 
intervention on recruitment rates in a multi-centre randomised trial. Trials 2015;16:211. 
 
StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP. 2013. 
 
Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M, et al. Methods to 
improve recruitment to randomised controlled trials: Cochrane systematic review and meta-
analysis. BMJ Open 2013;3:e002360. 
 
Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques 
RM, et al. Recruitment and retention of participants in randomised controlled trials: a review 
of trials funded and published by the United Kingdom Health Technology Assessment 
Programme. BMJ Open 2017;7:e015276. 
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
1 
 
Tables and Figures  
 
Table 1. Summary of the minimisation factors for the sites, presented overall and by 
randomised group 
Minimisation factor,  
n (%) 
On-site 
(n=20) 
Remote 
(n=17) 
Total 
(n=37) 
Population 
Large (≥500,000) 
Small (<500, 000) 
 
9 (45.0) 
11 (55.0) 
 
9 (52.9) 
8 (47.1) 
 
18 (48.7) 
19 (51.4) 
PI had trial experience 
Yes 
No  
 
14 (70.0) 
6 (30.0) 
 
11 (64.7) 
6 (35.3) 
 
25 (67.6) 
12 (32.4) 
Research nurse support 
Yes 
No 
 
13 (65.0) 
7 (35.0) 
 
12 (70.6) 
5 (29.4) 
 
25 (67.6) 
12 (32.4) 
 
Table 2.  Time between first contact with the site and key milestones in the set-up of the site 
Time in days between 
first contact and… 
On-site 
(n=20) 
Remote 
(n=17) 
Total 
(n=37) 
R&D submission 
N, Mean (SD) 
Median (IQR) 
 
19, 152.1 (103.2) 
113 (75, 200)  
 
14, 159.2 (128.1) 
134 (97, 155) 
 
33, 155.1 (112.6) 
119 (75, 189) 
R&D approval 
N, Mean (SD) 
Median (IQR) 
 
19, 176.2 (99.7) 
139 (99, 233) 
 
14, 179.3 (122.5) 
155 (107, 190) 
 
33, 177.5 (108.1) 
139 (107, 197) 
Site Initiation Visit 
(SIV) 
N, Mean (SD) 
Median (IQR) 
 
 
19, 156.7 (95.6) 
119 (85, 223) 
 
 
14, 172.2 (123.3) 
142 (97, 183) 
 
 
33, 163.3 (106.7) 
126 (89, 196) 
First recruit 
N, Mean (SD) 
Median (IQR) 
 
16, 269.9 (105.8) 
246 (196, 346) 
 
14, 251.4 (152.0) 
212 (154, 266) 
 
30, 261.2 (127.4) 
229 (188, 319) 
 
Table 3. Measures of recruitment per site, overall and by randomised group 
Measures of 
recruitment 
On-site 
(n=20) 
Remote 
(n=17) 
Total 
(n=37) 
Number of eligibility 
forms returned 
N, Mean (SD) 
Median (IQR) 
 
 
20, 23.5 (21.8) 
22 (3, 35) 
 
 
17, 26.9 (31.2) 
22 (8, 38) 
 
 
37, 25.1 (26.2) 
22 (5, 38) 
Proportion consenting / 
eligible  
N, Mean (SD) 
Median (IQR) 
 
 
18, 0.54 (0.29) 
0.63 (0.38, 0.71) 
 
 
14, 0.58 (0.20) 
0.53 (0.45, 0.71) 
 
 
32, 0.56 (0.25) 
0.59 (0.41, 0.71) 
Number of participants 
recruited 
N, Mean (SD) 
 
 
20, 9.7 (8.1) 
 
 
17, 10.9 (11.0) 
 
 
37, 10.2 (9.4) 
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Median (IQR) 10 (2, 17) 6 (5, 23) 6 (4, 17) 
Number of participants 
recruited from date 
final site opened 
N, Mean (SD) 
Median (IQR) 
 
 
 
20, 3.4 (3.3) 
4 (0, 6) 
 
 
 
17, 4.6 (5.5) 
2 (1, 5) 
 
 
 
37, 4.0 (4.4) 
4 (1, 5) 
 
Table 4. Return, and time to return, of participant and hospital forms by randomised group 
and time point, for all randomised participants 
Participant questionnaires On-site (n=193) 
Remote 
(n=185) 
Total 
(378) 
Week 6 Returned, n (%) 160 (82.9) 151 (81.6) 311 (82.3) 
Time to return, days 
Median (IQR) 
 
14 (7, 28) 
 
10 (5, 19) 
 
12 (6, 24) 
Week 12 Returned, n (%) 150 (80.2) 153 (84.5) 303 (82.3) 
Time to return, days 
Median (IQR) 
 
15 (7, 32) 
 
13 (7, 30) 
 
13 (7, 30) 
Week 26 Returned, n (%) 132 (68.4) 138 (74.6) 270 (71.4) 
Time to return, days 
Median (IQR) 
 
21 (12, 38) 
 
17 (9, 31) 
 
19 (10, 36) 
Week 52 Returned, n (%) 157 (81.4) 152 (82.2) 309 (81.8) 
Time to return, days 
Median (IQR) 
 
15 (8, 32) 
 
12 (6, 32) 
 
14 (7, 32) 
Hospital grip and range form 
   
Week 6 Returned, n (%) 169 (87.6) 161 (87.0) 330 (87.3) 
Time to return, days 
Median (IQR) 
 
10 (5, 19) 
 
7 (3, 16) 
 
9 (4, 17) 
Week 12 Returned, n (%) 142 (73.6) 149 (80.5) 291 (77.0) 
Time to return, days 
Median (IQR) 
 
10 (4, 20) 
 
11 (5, 21) 
 
11 (5, 21) 
Week 52 Returned, n (%) 126 (65.3) 131 (70.8) 257 (68.0) 
Time to return, days 
Median (IQR) 
 
17 (6, 40) 
 
12 (3, 33) 
 
14 (5, 35) 
 
 
Table 5. Time spent in hours for each method of communication 
 
On-site 
(n=20) 
Remote 
(n=17) 
Total 
(n=37) 
Telephone 
N, Mean (SD) 
Median (IQR) 
 
20, 0.9 (0.9) 
0.8 (0.2, 1.3) 
 
17, 1.6 (1.5) 
1.6 (0.5, 1.9) 
 
37, 1.2 (1.2) 
1.1 (0.3, 1.7) 
Email  
N, Mean (SD) 
Median (IQR) 
 
20, 5.3 (3.9) 
4.7 (2.1, 8.0) 
 
17, 5.3 (3.7) 
4.9 (2.2, 8.4) 
 
37, 5.3 (3.7) 
4.8 (2.2, 8.4) 
Face-to-face visit  
N, Mean (SD) 
Median (IQR) 
 
20, 20.9 (18.2) 
16.5 (11.8, 21.5)  
 
17, 12.9 (10.2) 
11.5 (8.3, 17.3) 
 
37, 17.2 (15.4) 
13.0 (10.5, 21.0) 
Total  
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N, Mean (SD) 
Median (IQR) 
20, 27.2 (21.1) 
21.9 (16.9, 27.78) 
17, 19.9 (12.4) 
19.6 (13.3, 24.8) 
37, 23.8 (17.8) 
21.5 (15.1, 24.8) 
 
Table 6. Cost of basic pay in £s for each method of contact including additional travel costs 
 On-site 
(n=20) 
Remote 
(n=17) 
Total 
(n=37) 
Telephone  
N, Mean (SD) 
Median (IQR) 
 
20, 25.6 (24.5) 
22.0 (4.6, 34.8) 
 
17, 45.6 (42.0) 
44.1 (13.9, 53.4) 
 
37, 34.8 (34.7) 
30.2 (9.3, 46.4) 
Email  
N, Mean (SD) 
Median (IQR) 
 
20, 148.7 (107.4) 
130.0 (57.8, 221.6) 
 
17, 148.5 (104.0) 
135.5 (60.3, 234.4) 
 
37, 148.6 (104.4) 
132.3 (60.3, 234.4) 
Face-to-face visit  
N, Mean (SD) 
Median (IQR) 
 
20, 582.8 (508.2) 
459.5 (327.2, 598.8)  
 
17, 359.9 (284.1) 
320.3 (232.1, 482.7) 
 
37, 480.3 (429.9) 
362.1 (292.4, 584.9) 
Total communication 
N, Mean (SD) 
Median (IQR) 
 
20, 757.1 (588.1) 
610.1 (471.1, 771.7) 
 
17, 553.9 (346.2) 
545.4 (371.3, 689.3) 
 
37, 663.8 (496.3) 
598.8 (421.0, 689.3) 
Travela 
N, Mean (SD) 
Median (IQR) 
 
20, 259.8 (183.6) 
211.3 (131.3   338.8) 
 
17, 173.2 (92.5) 
192.4 (119.3, 205.6) 
 
37, 220.0 (153.3) 
 192.8 (119.3, 285.1) 
Total communication 
and travel 
N, Mean (SD) 
Median (IQR) 
 
 
20, 1016.9 (743.0) 
870.8 (603.6, 1054.1) 
 
 
17, 727.1 (408.4) 
738.2 (486.2, 919.7) 
 
 
37, 883.8 (622.0) 
781.2 (588.1, 919.7) 
a not all sites were visited 
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Figure 1. Flow of sites in the embedded trial 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
40 Sites approached to take part in 
SWIFFT trial 
1 Excluded from randomisation 
(Chief Investigator site) 
39 Randomised 
20 Randomised to on-site set-up visit 
(includes one site manually allocated 
to the same site as same PI’s other 
site) 
19 Randomised to remote set-up visit 
  
2 Excluded post-randomisation 
(had not agreed to take part in host 
trial) 
17 Included in the intention-to-treat analysis 
16 Included in the per-protocol analysis 
 
 
20 Included in the intention-to-treat 
analysis  
18 Included in the per-protocol analysis 
 
20 Eligible for site set-up 
    18 Did get an on-site visit 
      2 Did not get an on-site visit (site 
wanted  
         remote visit) 
17 Eligible for site set-up 
    16 Did get a remote visit 
      1 Did not get a remote visit (site wanted  
         on-site visit) 
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Figure 2. Distribution of the number of participants recruited between on-site and remote groups 
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“What is new?” 
 
Key findings: 
 
• It was feasible to use remote or on-site visits for the initial contact with sites when 
setting up hospitals in a multi-centre surgical trial. 
 
What this adds to what was known? 
 
• The evidence from this study and the wider literature questions the need for on-site 
visits and the effectiveness of additional contact by Trial Co-ordinators on trial 
conduct. 
 
What is the implication, what should change now? 
 
• Trial Co-ordinators should consider being more selective as to when on-site visits are 
necessary and what type of additional contact with a site is required depending on 
the challenges that are specific to that site and the study.  
• Further research is necessary to improve our understanding of what constitutes 
optimal Trial Co-ordinator contact with sites and to evaluate strategies across a 
range of participant groups and settings. 
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